Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Increases By 22.7%

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) saw a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 386,500 shares, an increase of 22.7% from the November 15th total of 315,000 shares. Approximately 5.1% of the company’s shares are short sold. Based on an average trading volume of 3,150,000 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Investors Weigh In On Virpax Pharmaceuticals

An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC acquired a new position in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned about 1.17% of Virpax Pharmaceuticals at the end of the most recent reporting period. 32.23% of the stock is currently owned by institutional investors and hedge funds.

Virpax Pharmaceuticals Price Performance

Shares of VRPX traded up $0.10 during trading hours on Friday, reaching $0.40. The stock had a trading volume of 9,645,391 shares, compared to its average volume of 9,781,666. The firm has a 50-day moving average of $0.56 and a 200 day moving average of $0.77. Virpax Pharmaceuticals has a 52 week low of $0.29 and a 52 week high of $5.48.

Analyst Ratings Changes

Separately, Maxim Group reiterated a “hold” rating on shares of Virpax Pharmaceuticals in a research report on Wednesday, October 9th.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.